Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.44 |
| ▸ | HTR2A | P28223 | 10/20 | 0.42 |
| ▸ | HTR2C | P28335 | 7/20 | 0.42 |
| ▸ | HTR2B | P41595 | 5/20 | 0.40 |
| ▸ | HMGCR | P04035 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31295158 | 0.89 | TNKS2 (0.46) | TAAR1HTR2AHTR2CHTR2BHMGCR | |
| SCHEMBL21798808 | 0.85 | TAAR1 (0.52) | TAAR1HTR2AHTR2CHMGCRPDE4A | |
| SCHEMBL30207864 | 0.83 | PDE4A (0.52) | TAAR1HTR2AHTR2CHTR2BHMGCR | |
| SCHEMBL19667189 | 0.83 | PDE4A (0.52) | TAAR1HTR2AHTR2CHTR2BHMGCR | |
| SCHEMBL34463042 | 0.82 | TAAR1 (0.66) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL20562467 | 0.82 | TAAR1 (0.66) | TAAR1HTR2AHTR2CHTR2B | |
| SCHEMBL18894529 | 0.78 | SLC6A2 (0.49) | TAAR1 | |
| SCHEMBL30076924 | 0.78 | TDP1 (0.33) | TAAR1HTR2C | |
| SCHEMBL3568940 | 0.77 | HDAC3 (0.44) | TAAR1HTR2A | |
| SCHEMBL9886097 | 0.77 | TAAR1 (0.59) | TAAR1HTR2AHTR2CHTR2BHMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107918-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE (NO.5) LIMITED (GB) | 2016-12-28 | — | — | EP | disclosed |
| US-9273067-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273067-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273067-B2 | Pyrazolopyrimidine macrocycles as inhibitors of human immunodeficiency virus replication | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-03-01 | — | — | US | disclosed |
| WO-2015126737-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | WO | disclosed |
| WO-2015126737-A1 | PYRAZOLOPYRIMIDINE MACROCYCLES AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20150232481-A1 | Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150232481-A1 | Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150232481-A1 | Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232481-A1 | Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication | TYMP, EIF2AK2, MAVS | TAAR1 4877/4885HTR2A 4464/4885HTR2C 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.